Venus Remedies Board of Directors
Get the latest insights into the leadership at Venus Remedies. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Pawan Chaudhary | Chairman & Managing Director |
| Manu Chaudhary | Joint Managing Director |
| Peeyush Jain | Deputy Managing Director |
| Ashutosh Jain | Whole Time Director |
| Akshansh Chaudhary | Whole Time Director |
| Navdeep Sud | Non Executive Independent Director |
| Savita Gupta | Non Executive Independent Director |
| NPS Monga | Non Executive Independent Director |
| Jagdish Chander Sharma | Non Executive Independent Director |
| Anil Kumar | Non Executive Independent Director |
| Neha | Company Secretary & Compliance Officer |
Venus Remedies FAQs
The board at Venus Remedies consists of experienced professionals, including Pawan Chaudhary, Manu Chaudhary, and others, overseeing the company’s strategic and corporate governance.
Directors at Venus Remedies are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Pawan Chaudhary is the current chairman at Venus Remedies.
Executive directors at Venus Remedies are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Venus Remedies adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Venus Remedies, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
